+ 
  + 
Select Page
# 
An all-encompassing platform designed to meet
the growing demands of radiology practices and
large integrated delivery networks (IDNs).
Mach7 featured in
*Radiology Today*
Workflow Orchestration
for the Modern
Healthcare Enterprise
Revolutionizing
Healthcare Data
Management
Unifying all your images and
solving your integration needs
under one universal viewing platform
A Visual Data Experience
for the *Entire* Enterprise
# Introducing UnityVue
## A comprehensive suite of tools in a single platform, streamlining the entire radiology process from image acquisition to reporting.
# Awards & Publications
## CIO Bulletin
### 2022 50 Most Admired Companies to Watch
## Frost & Sullivan
### 2021 Global Enterprise Imaging Solutions Product Leadership Award
## Industry Tech Insights
### 2021 Top 10 Companies Revolutionizing Healthcare
!
### Control your transformation
Unify teams on an enterprise imaging roadmap that drives high quality patient care at your organization
### Do more with less complexity
Find new efficiency to save clinicians time and generate substantial cost savings
### Tap new opportunities
Leverage an overarching data view to drive quality, accuracy, and better clinical and financial outcomes
### Align for the future
Invest, grow, and embrace innovation with confidence
### Why Mach7
Mach7 is focused on the future of healthcare.
We give organizations unprecedented technology independence, flexibility, and interoperability so that nothing inhibits the flow of image data.
### Mach7 Enterprise Imaging Solution
With Mach7’s Enterprise Imaging Solution, your organization can bridge its legacy solutions to meet the full spectrum of multi-disciplinary imaging needs, and be positioned to grow, adapt, and innovate.
##### Thought Leadership Article
Teleradiology – Advancing Patient Care
During COVID -19 and Beyond
## Independence Through Innovation
120 Kimball Avenue, Suite 210
 South Burlington, VT 05403
120 Kimball Avenue,
 Suite 210
#### Collateral
#### Media
#### Company
#### Connect
 LinkedIn
 Twitter
 Facebook
# Mach7 Enterprise Imaging
## Align your strategies with your future healthcare vision.
## We are Your Definitive Technology Partner
The imaging systems that have become ingrained in healthcare over the last decade were not designed to support modern care delivery. Their locked-down, legacy technology makes it difficult–if not impossible–to fully leverage innovative technologies and novel strategies that improve outcomes, drive quality, and accelerate growth. Without a bridge from incumbent imaging systems, many organizations have found their digital transformation held captive. They need a definitive partner to guide them with flexible solutions and an enterprise strategy that works seamlessly with their current infrastructure.
Mach7 Technologies is that partner. Every member of our team is solely dedicated to enterprise imaging related initiatives and strategies – from professional services and support to product development to operations. We are not distracted by competing product lines or goals. We allow organizations to set their own course to enterprise imaging. We fill the connectivity gaps created by siloed departmental solutions so clinicians everywhere have a complete and cutting-edge view of the patient. Our platform integrates to anything, anywhere, anyhow so health systems are free to choose the technologies that are important to their physicians and patients. Through an unyielding focus on integration, workflow, and the elimination of complexity, we give organizations the ability to do more, and do better, with fewer resources and lower costs.
## We are not just another vendor.
Your enterprise imaging transformation can start now. Partner with Mach7 to streamline your image data, connect your departments, and satisfy patient care stakeholders, all without disruption to the delivery of care.
## Do you have questions?Our experts can answer them.
## Check out the latest from Mach7
#### 
Nov 14, 2024 | , 
Nov 11, 2024 | , 
# Investors
## Share Price
Founded in 2007, Mach7 Technologies excels as a market leader born of innovation and growing through strategic partnerships. Our team of industry experts brings hundreds of years of experience to customer partnerships where our culture of collaboration fosters innovation through new and improved patient-focused solutions. Mach7 brings a fresh approach to enterprise imaging management and workflow that pulls from the latest technologies and the brightest minds to deliver cutting edge solutions. The company provides award-winning vendor neutral archive technology to improve enterprise imaging data storage, sharing and interoperability across healthcare enterprises. Patent-awarded mobile technology extends this advanced enterprise imaging solution technology to mobile devices, further differentiating Mach7 as a healthcare technology leader.
Mach7 Technologies’ solutions are leveraged by global healthcare enterprises to unlock patient data, unleash care intelligence and fundamentally shift the management, sharing and use of medical imaging to power the healthcare enterprise ecosystem. Mach7 solutions allow patient data and patient care intelligence to be used in more meaningful ways to achieve systemic efficiencies, improve practitioner effectiveness and offer improved outcomes for patient.
### **Investor Relations**
**Françoise Dixon**
Head of Investor Relations
Mach7 Technologies Limited
ir@mach7t.com
+61 (0) 412 292 977
## Recent News
### Mach7 CEO Mike Lampron interview with Chris Titley of Morgans Financial Limited
Mach7 CEO Mike Lampron recently joined Chris Titley of Morgans Financial Limited for their Executive Focus Series podcast. In this interview, Mike discussed his history with the healthcare IT industry and with Mach7, provided insight on where the company fits into the healthcare IT space, and also provided some of his thoughts on relevant topics in the industry, such as the growing role of artificial intelligence (AI) and cybersecurity.
### Mach7’s Appearance at the Bell Potter Healthcare Conference 2024
Mach7’s CEO Mike Lampron recently presented at the 2024 Bell Potter Healthcare Conference. In this video, Mike provides an overview of Mach7, including discussion of our core solutions, our value proposition to healthcare organizations, enterprise imaging and its place in the market, and our FY24 results. You can watch the original video on YouTube, .
### FY24 Annual Report to the Shareholders
Mach7’s Annual Report to its Shareholders for Fiscal Year 2024 (FY24) has been released. 
### FY25 Q1 Results Investor Webinar
In this recorded webinar, CEO Mike Lampron sits down with Head of Investor Relations Francoise Dixon to provide an update on the Q1 results for FY25.
### FY24 Year-End Results Investor Webinar
CEO Mike Lampron sits down with CFO Dyan O’Herne and Head of Investor Relations Francoise Dixon to provide an update on results for fiscal year 2024.
The preliminary final report for FY 24 has been released. Click  to view it.
### FY24 Q4 Results Investor Webinar
Mach7 CEO Mike Lampron, along with Dyan O’Herne (CFO, Mach7), and Françoise Dixon (Head of Investor Relations, Mach7) sit down with investors in this recorded webinar to go over financial results of FY 24 Q4, fielding questions from the audience.
### FY24 Q3 Results Investor Webinar
In this recorded webinar session, Mike Lampron (CEO, Mach7), Dyan O’Herne (CFO, Mach7), and Françoise Dixon (Head of Investor Relations, Mach7) walk through the FY24 Q3 results and respond to questions from the audience.
### FY24 H1 Results Investor Webinar
Mach7 has released its FY24 H1 results. In this recorded webinar session, Mike Lampron (CEO, Mach7), Dyan O’Herne (CFO, Mach7), and Françoise Dixon (Head of Investor Relations, Mach7) walk through the results and respond to questions from the audience. .
****
### Mach7 Featured in RSM Report: Rising Global Demand for Medical Imaging Drives Mach7’s Future
Mach7 has been featured in a recent RSM Report *(Building from a solid foundation: The future of medtech in Australia).* In an article featured in the report, titled “Rising Global Demand for Medical Imaging Drives Mach7’s Future”, Mach7’s CEO, Mike Lampron, gives his perspective on how the company has positioned itself for growth in the medical imaging space.
### FY24 Q2 Results Investor Webinar
In this recorded webinar session, Françoise Dixon (Head of Investor Relations, Mach7) and Mike Lampron (CEO, Mach7) discuss the FY24 Q2 financial results and respond to questions from the audience.
### Stockhead Q+A with Mike Lampron, Mach7 CEO
Mach7’s CEO, Mike Lampron, recently sat down for a Q+A with , a journalistic news service dedicated to covering the stories of emerging ASX-listed companies. In the session, Mike discussed topics like Mach7’s FY23 results and FY24 outlook, his view on Mach7’s growth strategy, and the role of innovative technologies like cloud storage and AI adoption in the healthcare industry.
### FY24 Q1 Results Investor Webinar
In this recorded webinar session, Françoise Dixon (Head of Investor Relations, Mach7), Mike Lampron (CEO, Mach7), and Dyan O’Herne (CFO, Mach7) discuss the FY24 Q1 financial results and answer questions from the audience.
### Mach7 Technologies – Annual Report for FY23
Mach7’s Annual Report for Fiscal Year 2023 (FY23) is now available. You can .
### Mach7 Technologies Investor Day Presentation
Mach7 recently held an Investor Day in Sydney, Australia. This hybrid in-person/webinar presentation saw Mach7’s CEO, Mike Lampron, COO David Madaffri, and CFO Dyan O’Herne discuss the Company’s financials and sales updates. Key employees Jeff Hastings (Technical Sales Manager) and Kristi Creasy (Senior Clinical Specialist) also provided live demonstrations of Mach7’s products and their capabilities.
You can view the PowerPoint used in the livestream by .
### Mach7 Technologies FY23 Full Year Results
Mach7 is pleased to announce it has released its 2023 fiscal year (FY23) results. Highlights include record sales orders of A$40.3M (TCV), record revenue of A$30.1M, NPATA of A$7.2M, NPAT of -A$1.0M, CARR of A$20.6M, and ARR run rate of A$17.0M, among other results.  Additionally, Mach7 has also released its Preliminary Final Report, Directors’ Report and Audited Financial Statements, 
Mike Lampron (CEO, Mach7), Dyan O’Herne (Global CFO, Mach7), and Rebecca Thompson (Investor Relations, Mach7) walk through the FY23 results in this recorded webinar. You can view the presentation shown 
### Mach7 Technologies Q4 FY23 Results
Mach7 has released its Q4 results for Fiscal Year 2023 (FY2023). In this webinar, Rebecca Thompson (Investor Relations, Mach7) and Mike Lampron (CEO, Mach7) walk through the Q4 financials and respond to audience questions.
You can read the Q4 Business Update at the following link:
### Mach7 Technologies Q3 FY23 Results
Mach7 has released its Third-Quarter (Q3) results for Fiscal Year 2023 (FY2023). In this webinar, Rebecca Thompson (Investor Relations, Mach7) and Mike Lampron (CEO, Mach7) walk through the Q3 financials and respond to audience questions.
You can view the Q3 Business Update ASX release at the following link:
### Mach7 Technologies H1 FY23 Results
Mach7 has released its First Half (H1) results for Fiscal Year 2023 (FY2023). In this recorded webinar, Rebecca Thompson (Investor Relations, Mach7) and Mike Lampron (CEO, Mach7) walk through the financials and provide insight into the goings-on of the business and answer audience questions.
You can access supplemental materials to the recording at the following links:
### Mach7 Technologies Q2 FY23 Business Update
In this recording Mike Lampron (CEO, Mach7) delivered the Company’s second quarter (Q2) business update for Fiscal Year 2023 (FY23). He was joined on the call by Rebecca Thompson (Investor Relations, Mach7) and Dyan O’Herne (CFO, Mach7). You can read the full Q2 FY23 release on the ASX at this link: .
### Mach7 Technologies (ASX:M7T) at the Bell Potter Healthcare Conference 2022
Mike Lampron, Mach7’s Chief Executive Officer & Managing Director, recently presented at the 2022 Bell Potter Healthcare Conference. In this video, Mike provides a business overview of Mach7, including discussing our business, market, products, customers, global footprint, partners, value proposition, differentiators, revenue model, and our FY21 results. You can  to watch the original video on YouTube.
### Biotech Daily Article – Dr. Boreham’s Crucible: Mach7 Technologies
Mach7 has been featured in the November 11, 2022 edition of Biotech Daily’s “Dr. Boreham’s Crucible.” This is a great summary about the company, highlighting some of its current financials, and how it stacks up against some of its closest competitors. You can **,** or visit  for more.
### Mach7 Technologies – Annual Report for FY22
Mach7’s Annual Report for Fiscal Year 2022 (FY22) is now available. You can .
### FY22 Results Investor Webinar
The company has released its 2022 fiscal year (FY22) results, in which it reported record-setting financial results. Highlights include record revenues of $27.1M (up $8.1M or 42% yoy), annual recurring revenue (ARR) run rate $14.4M (up 7.5%), record positive operating cashflows of $6.3M (up $4.8M or 320% yoy), recrod gross margin of $26.1M or 96% (up $7.7M or 42% yoy), and EBITDA of $2.8M (up $4.6M or 253% yoy). . Additionally, Mach7 has also released its Preliminary Final report and Audited Full Year Accounts, .
In this recorded live stream, Mike Lampron (CEO, Mach7) and Steve Parkes (Global CFO, Mach7) walk through the FY22 results and answer questions from the audience. You can view the presentation used in the livestream **,** and access the livestream itself **.**
### Mach7 Technologies – Annual Report for FY21
Mach7 has published its Annual Report for Fiscal Year 2021. You can  or the image to the left.
### Bulls N’ Bears – Mach7 Technologies CEO Interview
Mike Lampron, CEO of Mach7, was recently interviewed by Matt Birney on his podcast Bulls N’ Bears to discuss the Company’s FY21 results.
### FY21 Results Investor Presentation
Mach7 has announced its 2021 fiscal year (FY21) results, in which it reported $25.6M in sales orders (total contract value), its highest on record. . Additionally, Mach7 has also released its Preliminary Final report and Audited Full Year Accounts, .
In this recorded live stream, Mike Lampron (CEO, Mach7), Jenni Pilcher (CFO, Mach7), and Andrew Keys (Investor Relations, Keys Thomas Associates) walk through the FY21 results and answer questions from the audience. You can view the presentation used in the livestream .
### Fourth Quarter FY21 Results
The company recently announced its Fourth Quarter FY21 Results, in which it reported 95% sales order growth for FY21, as well as a number of customer expansions and renewals. .
In this recorded live stream, Mike Lampron (CEO, Mach7), Jenni Pilcher (CFO, Mach7), and Andrew Keys (Investor Relations, Keys Thomas Associates) discuss the results and answer questions about the business and the healthcare IT market landscape.
### Third Quarter FY21 Results
In Mach7’s Third Quarter FY2021 Results, it reported record quarterly cash receipts, leading to strong operating cash flows. You can .
CEO Mike Lampron talks through the details **.** This **** also notes the highlights of the results, including comments from Mr. Lampron.
**You can click the thumbnail to watch the video interview.**